Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration [TheStreet.com]
Scinai Immunotherapeutics Ltd. - American Depositary Shares (SCNI)
Company Research
Source: TheStreet.com
JERUSALEM April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial Highlights Financial Results for Full-Year 2025 Revenues for the year ended December 31, 2025, were $1.3 million , compared to $0.7 million for the year ended December 31, 2024. The increase reflects continued expansion of Scinai's CDMO activities. R&D expenses for the year ended December 31, 2025, amounted to $2.4 million , compared to $5.5 million for the year ended December 31, 2024. The decrease was primarily due to lower allocation of employees and facility costs to the R&D business unit. Marketing, general and administrative expenses for the year ended December 31, 2025, were $2.
Show less
Read more
Impact Snapshot
Event Time:
SCNI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCNI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCNI alerts
High impacting Scinai Immunotherapeutics Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SCNI
News
- Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 PrioritiesPR Newswire
- Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm CollaborationPR Newswire
- Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026PR Newswire
- Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price [Yahoo! Finance]Yahoo! Finance
- Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid PricePR Newswire
SCNI
Sec Filings
- 4/1/26 - Form 20-F
- 3/26/26 - Form 3
- 3/23/26 - Form 6-K
- SCNI's page on the SEC website